Viatris, Inc. (VTRS)

NASDAQ: VTRS · IEX Real-Time Price · USD
-0.16 (-1.49%)
Aug 18, 2022 4:00 PM EDT - Market closed
Market Cap 13.04B
Revenue (ttm) 17.19B
Net Income (ttm) 760.80M
Shares Out 1.23B
EPS (ttm) 0.62
PE Ratio 17.08
Forward PE 3.20
Dividend $0.47 (4.44%)
Ex-Dividend Date Aug 23, 2022
Volume 5,060,301
Open 10.75
Previous Close 10.75
Day's Range 10.50 - 10.75
52-Week Range 9.45 - 15.60
Beta 1.20
Analysts Buy
Price Target 14.51 (+37.0%)
Earnings Date Aug 8, 2022

About VTRS

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agent... [Read more...]

Industry Pharmaceuticals
Employees 37,000
Stock Exchange NASDAQ
Ticker Symbol VTRS
Full Company Profile

Financial Performance

In 2021, Viatris's revenue was $17.89 billion, an increase of 49.73% compared to the previous year's $11.95 billion. Losses were -$1.27 billion, 89.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 21 analysts, the average rating for VTRS stock is "Buy." The 12-month stock price forecast is 14.51, which is an increase of 37.02% from the latest price.

Price Target
(37.02% upside)
Analyst Consensus: Buy
Stock Forecasts


Should I sell Viatris shares after Q2 results failed to meet revenue expectations?

Viatris Inc. (NASDAQ: VTRS) reported its second-quarter results on Monday and lowered the revenue outlook for the 2022 fiscal year. Michael Goettler, CEO of Viatris, said that because of strong operatio...

10 defensive stocks that can also provide you with growth and dividends over the long term

The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet.

Viatris' (VTRS) Q2 Earnings Beat, Revenues Miss Estimates

Viatris (VTRS) beats on Q2 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.

Viatris (VTRS) Surpasses Q2 Earnings Estimates

Viatris (VTRS) delivered earnings and revenue surprises of 8.64% and 0.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Viatris Reports Strong Second Quarter 2022 Results

Reports Total Revenues of $4.12 Billion; U.S. GAAP Net Earnings of $314 Million; Adjusted EBITDA of $1.48 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $803 Million; and Free Cash Flow...

Viatris Q2 Preview: Can Shares Snap Their Downtrend?

Even over the last month, when the S&P 500 has rallied for an 8% gain, Viatris shares have continued their downwards trajectory, declining 5.5% in value.

Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for

Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 Cheap Dividend Stocks Yielding More Than 4%

These two companies haven't performed well in the market recently, but that could be an opportunity for investors.

Other symbols: GILD

3 High-Yielding Dividend Stocks With Payout Ratios Over 100%

Are these dividend payments at risk?

Other symbols: ENBMO

Billionaires Are Piling Into These 2 Dividend-Paying Pharma Stocks

Billionaires are taking advantage of the weakness in Pfizer and Viatris this year.

Other symbols: PFE

7 Best Pharmaceutical Stocks to Buy Now

These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world.


2 Deeply Discounted Dividend Stocks With High Yields

These stocks pay a dividend yield of more than 4%.

Other symbols: CFG

Viatris Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022

PITTSBURGH , July 1, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to release its second quarter 2022 financial results on Monday, August 8 before the open of the U.S. financial markets. Chief ...

Viatris (VTRS) Up 13.7% Since Last Earnings Report: Can It Continue?

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?

7 High-Quality Dividend Stocks With High Yields

These are the best dividend stocks with high yields to invest in now. BIP, EPR, FL, KMI, KHC, VTRS, and WBA can make great investments.


2 Bruised Dividend Stocks to Buy While They're Cheap

Lower share prices won't stop them from hiking their dividends.

Other symbols: AFCG

Why Shares of Viatris Climbed 18.8% in May

The company reported improved net income and free cash flow in the last quarter.

3 Great Dividend Stocks to Buy in June

Investors should be able to count on recurring income with these stocks.

Other symbols: ABBVNVS

3 High-Yielding Dividend Stocks That Are Trading Below Their Book Values

These stocks are incredibly cheap, and aren't as risky as their low multiples suggest they might be.

Other symbols: CPARA

Viatris to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

PITTSBURGH , May 20, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced the company will participate in the Goldman Sachs 43rd Annual Global Healthcare Co...

Viatris Publishes Sustainability Report Highlighting 2021 Progress, Achievements and Goals

PITTSBURGH , May 16, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today published its 2021 Sustainability Report, outlining the company's 2021 achievements and prog...

2 Stocks That Are Ridiculously Cheap Right Now

They present very different kinds of bargains.

Other symbols: TDOC

3 Dirt-Cheap Stocks You Can Buy Right Now

These stocks are inexpensive yet have solid underlying businesses.

Other symbols: BNTXPFE

Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus

Viatris Inc (NASDAQ: VTRS) reported Q1 FY22 sales of $4.18 billion, down 5% Y/Y (-1% on an operational basis), below the consensus of $4.23 billion. Brands performed better than expectations, such as Li...

Viatris' (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

Viatris (VTRS) beats on Q1 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.